AstraZeneca Reports Positive Phase III Results for Forxiga in Children with Type 2 Diabetes
UK-based AstraZeneca (AZ, NASDAQ: AZN) has announced promising results from the Phase III T2NOW study...
Sandoz Becomes Independent After Spin-Off from Novartis
Switzerland-based generic and biosimilar drug maker Sandoz (SWX: SDZ) officially became a fully independent company...
Eli Lilly Acquires Point Biopharma to Enhance Oncology Portfolio
Eli Lilly (NYSE: LLY) announced last week its agreement to acquire radiopharmaceutical company Point Biopharma...
Sanofi’s Nexviazyme Approved in China as Enzyme Replacement Therapy for Pompe Disease
Sanofi’s (NASDAQ: SNY) next-generation enzyme replacement therapy (ERT), Nexviazyme (avalglucosidase alfa), has received marketing approval...
NMPA and NHC Tighten Regulations on Etomidate and Modafinil
The National Medical Products Administration (NMPA) and the National Health Commission (NHC) have jointly issued...
Hangzhou HealSun Biopharm Secures RMB 200 Million in Series B+ Financing
Hangzhou HealSun Biopharm Co., Ltd., a Chinese contract research organization (CRO) and contract development and...
Viatris to Divest Women’s Health and API Businesses, Offloading 12 Factories and 6,000 Employees
US-based Viatris Inc. (NASDAQ: VTRS) is set to divest its women’s health business, API operations...
Janssen and Sanofi Partner for Development of First-in-Class E. coli Vaccine
The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) has entered into a strategic...
Takeda Initiates Global Withdrawal of Exkivity Following Phase III Trial Results
Japan-based Takeda (TYO: 4502) has announced the voluntary global withdrawal of its tyrosine kinase inhibitor...
Kyowa Hakko Kirin to Acquire Orchard Therapeutics for $477.6 Million
Japan-based Kyowa Hakko Kirin is poised to acquire UK-headquartered Orchard Therapeutics plc for a total...
PharmaEssentia Announces Licensing Agreement with WuXi Biologics for Antibody Development
Taiwan-based PharmaEssentia Corporation (TPE: 6446, FRA: 8Z1) has entered into a licensing agreement with China’s...
Boehringer Ingelheim Collaborates with Zeiss Medical Technology on Retinal Disease Detection
Germany’s Boehringer Ingelheim (BI) has entered into a collaboration agreement with fellow German firm Zeiss...
Guangdong Medicine Exchange Announces Volume-Based Procurement for Medical Devices
The Guangdong Medicine Exchange has issued three notifications regarding the volume-based procurement (VBP) of medical...
Cardinal Health Acquires MedAlliance for $1.135 Billion to Enhance Vascular Intervention Portfolio
US-based Cardinal Health (NYSE: CAH) has announced the acquisition of Swiss firm MedAlliance for a...
Hong Kong Government Partners with AstraZeneca, Tigermed, and Simcere to Boost Innovation
The government of the Hong Kong Special Administrative Region has entered into significant partnership agreements...
Everest Medicines and Calliditas Present New Data on Nefecon for IgA Nephropathy
Everest Medicines (HKG: 1952), in partnership with Calliditas Therapeutics AB (Nasdaq: CALT), recently presented new...
Zhaoke Ophthalmology Completes Patient Enrollment for Phase III Trials of TAB014 and Epinastine
Zhaoke Ophthalmology Ltd (HKG: 6622), a former subsidiary of Lee’s Pharmaceutical Holdings Ltd (HKG: 0950),...
Amicus Therapeutics Secures FDA Approval for Pombiliti and Opfolda Combination Therapy
Amicus Therapeutics (NASDAQ: FOLD), headquartered in the United States, has announced that it has received...
Vela Diagnostics Partners with SRL Inc. to Expand Molecular Diagnostics in Japan
Singapore-based Vela Diagnostics, a global leader in integrated molecular solutions for diagnosing infectious diseases and...
Transcenta Secures FDA Approval for Phase III Trial of Osemitamab
China-based Transcenta Holding Ltd (HKG: 6628) has announced that it has received approval from the...